Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis

Patricia B Williams1,2, Elizabeth Crandall2, John D Sheppard1,21Thomas R Lee Center for Ocular Pharmacology, 2Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, A, USAAbstract: Over 50% of patients who seek treatment for allergies present with ocular &shy;symptoms. Our cu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Patricia B Williams, Elizabeth Crandall, John D Sheppard
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/8b86330d137c464e846053ee85db4488
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8b86330d137c464e846053ee85db4488
record_format	dspace
spelling	oai:doaj.org-article:8b86330d137c464e846053ee85db44882021-12-02T07:45:58ZAzelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis1177-54671177-5483https://doaj.org/article/8b86330d137c464e846053ee85db44882010-09-01T00:00:00Zhttp://www.dovepress.com/azelastine-hydrochloride-a-dual-acting-anti-inflammatory-ophthalmic-so-a5183https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Patricia B Williams1,2, Elizabeth Crandall2, John D Sheppard1,21Thomas R Lee Center for Ocular Pharmacology, 2Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, A, USAAbstract: Over 50% of patients who seek treatment for allergies present with ocular &shy;symptoms. Our current ability to control ocular allergic symptoms is greater than ever before. Newer dual-acting topical eyedrops attack multiple facets of the allergic cascade. Azelastine has antihistaminic effects providing immediate relief, mast cell stabilization providing early-phase intervention, and inhibition of expression and activation of anti-inflammatory mediators which characterize the late phase of the immune reaction. The ophthalmic eyedrop formulation is approved for treatment of allergic conjunctivitis in adults and children aged over 3 years. In clinical trials comparing azelastine with other dual-acting eyedrops, such as levocabastine and olopatadine, azelastine was reported to be slightly less efficacious and to sting briefly upon administration. Even so, many patients experienced the full benefit of symptom relief, and preferred azelastine. As a broad-spectrum drug, azelastine offers many desirable properties for management of ocular allergies. Because it can often produce maximal effect with just twice-daily dosing, azelastine is a particularly good choice for the allergic population in whom minimizing exposure to topical products and preservatives is a key concern.Keywords: allergic conjunctivitis, dual acting anti-inflammatory, H1 receptor antagonism, mast cell stabilization, inflammatory mediator inhibition Patricia B WilliamsElizabeth CrandallJohn D SheppardDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 993-1001 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Patricia B Williams Elizabeth Crandall John D Sheppard Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
description	Patricia B Williams1,2, Elizabeth Crandall2, John D Sheppard1,21Thomas R Lee Center for Ocular Pharmacology, 2Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, A, USAAbstract: Over 50% of patients who seek treatment for allergies present with ocular &shy;symptoms. Our current ability to control ocular allergic symptoms is greater than ever before. Newer dual-acting topical eyedrops attack multiple facets of the allergic cascade. Azelastine has antihistaminic effects providing immediate relief, mast cell stabilization providing early-phase intervention, and inhibition of expression and activation of anti-inflammatory mediators which characterize the late phase of the immune reaction. The ophthalmic eyedrop formulation is approved for treatment of allergic conjunctivitis in adults and children aged over 3 years. In clinical trials comparing azelastine with other dual-acting eyedrops, such as levocabastine and olopatadine, azelastine was reported to be slightly less efficacious and to sting briefly upon administration. Even so, many patients experienced the full benefit of symptom relief, and preferred azelastine. As a broad-spectrum drug, azelastine offers many desirable properties for management of ocular allergies. Because it can often produce maximal effect with just twice-daily dosing, azelastine is a particularly good choice for the allergic population in whom minimizing exposure to topical products and preservatives is a key concern.Keywords: allergic conjunctivitis, dual acting anti-inflammatory, H1 receptor antagonism, mast cell stabilization, inflammatory mediator inhibition
format	article
author	Patricia B Williams Elizabeth Crandall John D Sheppard
author_facet	Patricia B Williams Elizabeth Crandall John D Sheppard
author_sort	Patricia B Williams
title	Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
title_short	Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
title_full	Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
title_fullStr	Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
title_full_unstemmed	Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
title_sort	azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/8b86330d137c464e846053ee85db4488
work_keys_str_mv	AT patriciabwilliams azelastinehydrochlorideadualactingantiinflammatoryophthalmicsolutionfortreatmentofallergicconjunctivitis AT elizabethcrandall azelastinehydrochlorideadualactingantiinflammatoryophthalmicsolutionfortreatmentofallergicconjunctivitis AT johndsheppard azelastinehydrochlorideadualactingantiinflammatoryophthalmicsolutionfortreatmentofallergicconjunctivitis
_version_	1718399168326664192

Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis

Ejemplares similares